Josephine Connolly-Schoonen
This study will examine if a short-term, reduced protein diet for the 3-day period prior to and on the day of each of the first 4 chemotherapy cycles and 4 days prior to primary breast surgery is well tolerated and adhered to by patients with stage II or III estrogen receptor positive (ER+) human epidermal growth factor receptor negative (HER2-) breast cancer (BC) receiving neoadjuvant chemotherapy (NAC).
There has been recent interest in the potential anti-cancer effects of nutrition interventions, although little is known about how individual patients' diets can impact the tumor microenvironment, and potentially patient outcomes. This is despite long-standing patient and healthcare provider interest in this type of adjunctive therapy. Therein lies a significant opportunity to develop nutritional recommendations that could exert antitumor effects with minimal, if any, side effects. To meet this opportunity, dietary alterations in cancer patients have been implemented in a surprisingly small nu…
Inclusion Criteria: * 18-75 years of age at time of consent * Stage II or III ER+ HER2- breast cancer patients scheduled to receive standard of care neoadjuvant chemotherapy * Willingness to consume study foods exclusively during the 20 days of prescribed diet Exclusion Criteria: * Any food allergy that may result in anaphylactic response or death (due to possible food allergen cross-contamination in the metabolic kitchen) * Habitual low protein intake, less than or equal to 1.0 g per kilogram adjusted body weight, based on a screening dietary habits questionnaire score * Vegans or vegetari…
Consume an intermittent, reduced protein diet for a total of 20 feeding days over the course of neoadjuvant treatment (at the time of the first four chemotherapy cycles and prior to surgery)
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.